MedPath

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Completed
Conditions
Lymphoma, Mantle-Cell
Interventions
Registration Number
NCT03647124
Lead Sponsor
Celgene
Brief Summary

The purpose of this study is to investigate and characterize the association of lenalidomide with tumor flare reaction and high tumor burden in participants with relapsed or refractory mantle cell lymphoma.

Detailed Description

This is a European multinational, retrospective, non-interventional study of participants with relapsed or refractory mantle cell lymphoma (R/R MCL). Potential sites will be identified where R/R MCL participants have been treated with lenalidomide. Site inclusion will be limited to countries where lenalidomide is reimbursed for this indication.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
105
Inclusion Criteria

Received at least one dose of lenalidomide commencing after 08 July 2016 for the treatment of relapsed refractory mantle cell lymphoma.

Informed consent of the patient or an authorized third person or authority, if required by law, given prior to data collection.

Patient must be ≥18 years of age at the time of signing the informed consent form.

Exclusion Criteria
  1. Patients will be excluded if they were participating in an interventional clinical trial during the treatment period under observation in this Post Authorization Safety Study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Lenalidomide treated Relapsed or refractory mantle cell lymphoma (R/R-MCL) participants in EuropeLenalidomide-
Primary Outcome Measures
NameTimeMethod
To quantify and characterize the event of TFR by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting.Approximately 8.5 years

To quantify and characterize the event of TFR by tumor burden (assessed based on the last CT scan performed within a maximum of 2 months prior to initiation of administration of lenalidomide) in R/R MCL patients treated with lenalidomide in a real-world setting.

Secondary Outcome Measures
NameTimeMethod
To quantify and characterize the proportion of early deaths by tumor burden in R/R MCL patients treated with lenalidomide in a real-world settingApproximately 8.5 years

To quantify and characterize the proportion of early deaths (defined as deaths within 20 weeks of initial administration of lenalidomide) by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting.

Trial Locations

Locations (79)

Local Institution - 614

🇮🇹

Milano, Italy

Local Institution - 101

🇦🇹

Wien, Austria

Local Institution - 303

🇫🇷

Le Chesnay Cedex, France

Centre Hospitalier de Versailles André Mignot

🇫🇷

Le Chesnay, France

Institution: Hopital Prive du Confluent

🇫🇷

Nantes, France

Local Institution - 308

🇫🇷

Nantes, France

Local Institution - 202

🇪🇸

Salamanca, Spain

Hospital Clínico Universiatrio de Salamanca

🇪🇸

Salamanca, Spain

Ospedale Policlinico San Martino - IRCCS

🇮🇹

Genova, Italy

Istituto Clinico Humanitas IRCCS

🇮🇹

Milano, Italy

Fondazione IRCCS Ca' Cranda, Ospedale Maggiore Policinico

🇮🇹

Milano, Italy

Local Institution - 105

🇦🇹

Graz, Austria

LKH Graz Medizinische Universitätsklinik

🇦🇹

Graz, Austria

LKH Hochsteiermark, Standort Leoben

🇦🇹

Leoben, Austria

Centre Hospitalier de Saint-Quentin

🇫🇷

Saint Quentin Picardie, France

Local Institution - 256

🇩🇪

Wuerzburg, Germany

Universitaetsklinikum Wuerzburg

🇩🇪

Wuerzburg, Germany

General University Hospital of Alexandroupolis

🇬🇷

Alexandrouppoli, Greece

Local Institution - 506

🇬🇷

Athens Goudi, Greece

General Anti-Cancer Hospital "Agios Savvas"

🇬🇷

Athens, Greece

Local Institution - 501

🇬🇷

Athens, Greece

Private hospital "Iatriko Psychikou", Athens

🇬🇷

Athens, Greece

General University Hospital of Athens "LAIKO", Athens

🇬🇷

Athens, Greece

Local Institution - 502

🇬🇷

Athens, Greece

General University Hospital "Attikon"

🇬🇷

Chaidari, Greece

Metaxa Cancer Hospital, Athens

🇬🇷

Piraeous, Greece

Local Institution - 511

🇬🇷

Rio, Patras, Greece

Theageneio General Hospital, Thessaloniki

🇬🇷

Thessaloniki, Greece

Local Institution - 607

🇮🇹

Genova, Italy

Istituto Europeo di Oncologia

🇮🇹

Milano, Italy

Azienda Ospedaliera Niguarda Ca' Granda

🇮🇹

Milano, Italy

Local Institution - 603

🇮🇹

Milano, Italy

Local Institution - 617

🇮🇹

Padova, Italy

Azienda Ospedaliera di Padova - U.O.C. di Gastroenterologia

🇮🇹

Padova, Italy

Local Institution - 613

🇮🇹

Padova, Italy

Azienda Ospedaliero - Universiaria di Parma

🇮🇹

Parma, Italy

Amyloidosis Research & Treatment Center, Fondazione Irccs Policlinico San Matteo

🇮🇹

Pavia, Italy

Local Institution - 609

🇮🇹

Pavia, Italy

Local Institution - 610

🇮🇹

Pisa, Italy

Azienda Ospedaliero Universitaria Pisana

🇮🇹

Pisa, Italy

AKH Wien, Universitaetsklinik fuer Innere Medizin III

🇦🇹

Wien, Austria

Local Institution - 104

🇦🇹

Leoben, Austria

Salzburger Landeskliniken - Universitaetsklinikum Salzburg

🇦🇹

Salzburger, Austria

Local Institution - 102

🇦🇹

Salzburg, Austria

Landesklinikum Wiener Neustadt

🇦🇹

Wiener Neustadt, Austria

Local Institution - 103

🇦🇹

Wiener Neustadt, Austria

Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Universitaire Pitie Salpetriere (Hopital Pitie-Salpetriere)

🇫🇷

Paris, France

Institut Universitaire du Cancer Toulouse - Oncopole

🇫🇷

Toulouse Cedex 9, France

Local Institution - 305

🇫🇷

Toulouse CEDEX 9, France

Berufsausuebungsgemeinschaft Kiehl/Stein

🇩🇪

Frankfurt/ Oder Brandenburg, Germany

Praxis fuer Haematolgie, Onkologie und Palliativmedizin

🇩🇪

Leipzig, Germany

Local Institution - 601

🇮🇹

Busto Arsizio, Italy

Ospedale di Busto Arsizio - ASST Valle Olona

🇮🇹

Busto Arsizio, Italy

Arcispedale Santa Maria Nuova - AUSL Reggio Emilia

🇮🇹

Reggio Emilia, Italy

Local Institution - 602

🇮🇹

Reggio Emilia, Italy

Infermi Hospital

🇮🇹

Rimini, Italy

Local Institution - 605

🇮🇹

Rimini, Italy

Policlinico Umberto I , Universita La Sapienza

🇮🇹

Roma, Italy

Local Institution - 611

🇮🇹

Rome, Italy

Local Institution - 608

🇮🇹

Siena, Italy

Universita di Siena -Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte

🇮🇹

Siena, Italy

Azienda Ospedaliera Citta della Salute e della Scienza di Torino

🇮🇹

Torino, Italy

Local Institution - 616

🇮🇹

Torino, Italy

Presidio Ospedaliero Molinette - A.O.U. Citta della Salute e della Scieza

🇮🇹

Torino, Italy

Local Institution - 606

🇮🇹

Venezia - Mestre, Italy

Ospedale Dell'Angelo Di Mestre

🇮🇹

Venezia, Italy

HagaZiekenhuis van Den Haag - Juliana Kinderziekenhuis (JKZ) - Leyweg

🇳🇱

Den Haag, Netherlands

Local Institution - 401

🇳🇱

Den Haag, Netherlands

Hospital universitario de Alava

🇪🇸

Alava País Vasco, Spain

Local Institution - 204

🇪🇸

Alava, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Local Institution - 207

🇪🇸

Madrid, Spain

Local Institution - 201

🇪🇸

Malaga, Spain

Hospital Regional Universitario Carlos Haya

🇪🇸

Malaga, Spain

Hospital de Orense

🇪🇸

Ourense, Spain

Local Institution - 206

🇪🇸

Ourense, Spain

Local Institution - 209

🇪🇸

Santa Cruz De Tenerife, Spain

Local Institution - 205

🇪🇸

Sevilla, Spain

Nuestra Senora de Valme

🇪🇸

Sevilla, Spain

© Copyright 2025. All Rights Reserved by MedPath